Metabolic disorders in schizophrenic patients treated with Clozapine;Trastornos metabólicos en pacientes esquizofrénicos tratados con Clozapina

Revista Chilena de Neuro-Psiquiatria

Volumn 42, Issue 1, 2004, Pages 37-42

  Muñoz, Patricia ^a   Gallardo, Roberto ^a  

^a University of Wales   (Chile)

Author keywords

Clozapine; Diabetes mellitus; Hyperlipidemia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE;

ARTICLE; BODY WEIGHT; CASE REPORT; DRUG DOSE REGIMEN; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; LIPID ANALYSIS; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; NUTRITIONAL ASSESSMENT; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

EID: 31544476869     PISSN: 00347388     EISSN: 07179227     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, Diabetes mellitus, and lipid abnormalities. Canadian J Psychiat 2001; 46: 273-281
2. Rigalleau V, Gatta B, Bonnaud S, Masson M, Bourgeois ML, Vergnot V, et al. Diabetes as a result of atypical antipsychotic drugs. A report of three cases. Diabetic Medicine (England) 2000; 17: 484-486
3. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, Diabetes mellitus, weight gain, and lipid abnormalities; A five-year naturalistic study. Am J Psychiatry 2000; 157: 975-981
4. Mir S, Taylor D. Atypical antipsychotics and hyperglycemia. Int Clinical psychopharmacology 2001; 16: 63-73
5. Wu G, Dias P, Chun W, Li G, Kumar S, Singh S. Hyperglycemia, hyperlipidemia and periodic paralysis; a case report of new side effects of Clozapine. Yuenyang Center of Mental Heath, Yuenyang, PR China. Prog. Neuropharmacol. Biol Psychiatr (England) 2000; 24: 1395-1400
6. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy (USA) 2000; 20: 844-847
7. Brugman NJ, Cohen D, De Vries RH. Diabetes mellitus ontstaan na behandeling met clozapine. Ned Tijdschr Geneeskd 2000; 144: 437-439
8. Meltzer HY. An overview of the mechanism of the action of clozapine. J Clin Psychiatry 1994; 55 (Suppl B): 47-52
9. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. A novel antipsychotics and new onset Diabetes. Biol Psychiatry 1998; 44: 778-783
10. Chauloff F, Laude D, Baudrie V. Effects of the 5-HT1c/5-HT2 receptor agonists DOI and alpha-methyl-5HT on plasma glucose and insuline levels in the rat. Eur J Pharmacol 1990; 1887: 435-443
11. Bustillo JR, Buchaman RW, Irish D, Breier A. Differential effect of Clozapine on weight; a controlled study. Am J Psychiatry 1996; 153: 817-819
12. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotics-induced weight-gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1689
13. Dursun SM, Szemis A, Andrews H, Reveley MA. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiat Neurosc 1999; 24: 453-455
14. Arteaga A. Etiopatogenia de la obesidad. Bol Esc Med PUC 1997; 26:13-17
15. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24:59-73
16. Wetterling T, Mubigbrodt H. Weigth gain: side effect of atypical neuroleptics? J Clin Psychopharmacology 1999; 19: 316-321
17. López-Mato A, Rovner J, Vieitez A, Illa G, Boullosa O. Estudio abierto randomizado sobre el uso de Ranitidina a diferentes dosis para el control del aumento de peso asociado a la administración de Olanzapina. Rev Arg Psiquiat 2003; XIV: 5-16
18. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Review article. Acta Psych Scand 1999; 100: 3-16
19. Taylor D, McAskill R. Atypical antipsychotics and weigth gain. A sistematic review. Act Psychiatr Scand 2000; 101: 416-432
20. Baptista T, Kin NM, Beaulieu S. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35:205-219
21. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290-296
22. Kato MM, Goodnick PJ. Antipsychotic medication; effects on regulation of glucose and lipids. Expert Opin Pharmacother 2001; 2: 1571-1582